$TIL

Instil Bio, Inc. (TIL): Submission of Matters to a Vote of Security Holders

Instil Bio, Inc. (TIL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. til-20260611 FALSE 0001789769 0001789769 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
Published Jun 11, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$TIL
Neutral
high confidence
Mentioned
$TIL
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TILNeutralLow
01

Why it matters

This is a post-meeting administrative disclosure covering (1) election of two Class II directors and (2) ratification of the independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

02

Market read

No new fundamental catalyst; the disclosure mainly confirms governance outcomes and auditor selection.

03

What to watch

Traders may still check the referenced April 24, 2026 definitive proxy for any contested items or governance changes not captured in this brief 8-K summary.

Relevance 6/10Novelty 2/10Timing: Filed June 11, 2026 after the Annual Meeting vote results

Background

The company’s 8-K Item 5.07 reports certified results from its 2026 Annual Meeting of Stockholders held June 11, 2026.

Company-level read

Ticker impact

$TILNeutralHigh confidence
Context

Instil Bio filed an 8-K reporting Annual Meeting voting results: Class II director elections and ratification of RSM US LLP as auditor for 2026.

Expected impact

Likely minimal near-term impact; any move would be sentiment/flow-driven rather than fundamentals.

Evidence & confidence

The filing only summarizes stockholder votes (board nominees and auditor ratification) with no new business, clinical, regulatory, or financial datapoints.

Market effects

None—auditor ratification and director election are company-specific governance items.

None indicated.

None indicated.

Counterpoint

Even routine governance filings can matter if they signal board/audit committee stability, but this text provides no such change details.

Key entities

  • Instil Bio, Inc.

    Nasdaq-listed company filing the 8-K with Annual Meeting voting results.

  • RSM US LLP

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

  • George Matcham

    Elected Class II director (Votes For: 3,683,114; Withheld: 742,925; Broker Non-Votes: 1,331,880).

  • Neil Gibson

    Elected Class II director (Votes For: 3,603,901; Withheld: 822,138; Broker Non-Votes: 1,331,880).

Related articles

$TILMed

Instil Bio, Inc. (TIL): Results of Operations and Financial Condition

Instil Bio, Inc. (TIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-26er.htm EX-99.1 Document Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing in

$TILMedAI 9/10

TIL Limited Reports Q4FY26 & Full Year FY26 Results

TIL Limited (NSE: TIL) reported Q4FY26 and full-year FY26 results. FY26 revenue was Rs. 337.36 Cr vs Rs. 343.07 Cr in FY25, with machine sales up 4% to Rs. 265.33 Cr. The company cited lower other income and financing/currency and one-time settlement expenses. It won major orders (including Rs. 66.75 Cr CONCOR ReachStackers) and approved a majority-stake acquisition of Tulip Compression (completed May 2026) to enter LNG/hydrogen powerpacks and related manufacturing.

$BIRKMed

EQS-News: Birkenstock Holding plc: BIRKENSTOCK ANNOUNCES LAUNCH OF SECONDARY OFFERING AND CONCURRENT SHARE REPURCHASE

Birkenstock Holding plc (BIRKENSTOCK) said it will start an underwritten secondary public offering of $1.0 billion of its ordinary shares sold by an affiliate of L Catterton. Birkenstock will not receive proceeds. After completion, it authorized up to $500 million of share repurchases via redemption at the offering price. J.P. Morgan is the underwriter.

$INTCMedAI 8/10

Why Intel Is Wise to Issue $20 Billion in Stock Right Now

Intel increased its planned stock offering from $15 billion to $20 billion, selling additional shares at $95 each to raise about $19.7 billion net, according to the company. The announcement followed a roughly 4% stock drop. Proceeds will be used for general corporate purposes including capex and working capital, supporting Intel Foundry and CPU demand.

Instil Bio, Inc. (TIL): Submission of Matters to a Vote of Security Holders — alphai